COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:
NIH staff guidance on coronavirus (NIH Only)

EicOsis EC5026 Granted Fast Track Designation by FDA for Neuropathic Pain

Thursday, April 9, 2020

DAVIS, Calif., April 9, 2020 /PRNewswire/ -- EicOsis LLC, a pharmaceutical startup developing a new class of oral non-narcotic analgesics based on inhibition of the soluble Epoxide Hydrolase (sEH) enzyme, announced today that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to its lead drug candidate, EC5026, for the treatment of neuropathic pain. Fast Track designation confers important benefits, including the potential eligibility for Priority Review of a New Drug Application. Read more here.